Skip to main
ACIU
ACIU logo

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, utilizing proprietary technology platforms to develop innovative small molecules, antibodies, and vaccines. The promising early results from the PD active immunotherapy ACI-7104.056 indicate a 20-fold increase in antibodies targeting pathogenic variants of aSyn, suggesting significant therapeutic potential. The company’s strategic focus on enhancing patient identification and delivering effective, user-friendly treatments aligns well with current trends in Alzheimer’s disease management, positioning AC Immune favorably within a rapidly evolving market.

Bears say

AC Immune SA operates in a high-risk environment typical of the biopharmaceutical industry, characterized by potential clinical readout setbacks and safety concerns. The company is also confronting regulatory uncertainty that may hinder the advancement of its therapeutic and diagnostic products targeting misfolded proteins. Additionally, the increasingly complex and price-sensitive nature of the commercial markets presents further challenges that could negatively impact the profitability and market acceptance of its product candidates.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.